Labcorp Holdings Inc. $LH Shares Purchased by Lido Advisors LLC

Lido Advisors LLC lifted its position in Labcorp Holdings Inc. (NYSE:LH – Free Report) by 365.0% in the 3rd quarter, Holdings Channel reports. The fund owned 4,673 shares of the medical research company’s stock after acquiring an additional 3,668 shares during the quarter. Lido Advisors LLC’s holdings in Labcorp were worth $1,440,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Dimensional Fund Advisors LP boosted its position in shares of Labcorp by 2.2% during the first quarter. Dimensional Fund Advisors LP now owns 1,332,775 shares of the medical research company’s stock valued at $355,569,000 after purchasing an additional 28,584 shares in the last quarter. Royal Bank of Canada grew its stake in Labcorp by 19.4% in the first quarter. Royal Bank of Canada now owns 820,442 shares of the medical research company’s stock worth $218,901,000 after purchasing an additional 133,549 shares during the period. Diamond Hill Capital Management LLC Investment Advisor purchased a new stake in Labcorp in the second quarter worth $168,222,000. Bank of New York Mellon Corp bought a new position in Labcorp in the second quarter worth $142,125,000. Finally, Madison Asset Management LLC bought a new position in Labcorp in the second quarter worth $133,460,000. Hedge funds and other institutional investors own 95.94% of the company’s stock.

Labcorp Stock Performance

Shares of LH opened at $370.69 on Monday. The company has a quick ratio of 1.22, a current ratio of 1.41 and a debt-to-equity ratio of 0.60. The stock has a market cap of $30.10 billion, a P/E ratio of 30.41, a P/E/G ratio of 2.09 and a beta of 0.86. The business’s 50 day moving average price is $329.60 and its 200-day moving average price is $292.58. Labcorp Holdings Inc. has a 52 week low of $245.00 and a 52 week high of $375.10.

Labcorp (NYSE:LH – Get Free Report) last posted its quarterly earnings data on Wednesday, October 28th. The medical research company reported $4.78 earnings per share for the quarter, beating analysts’ consensus estimates of $4.64 by $0.14. Labcorp had a return on equity of 17.13% and a net margin of 6.88%. The company had revenue of $3.81 billion during the quarter, compared to analyst estimates of $3.76 billion. During the same quarter last year, the company earned $4.18 EPS. The firm’s revenue for the quarter was up 6.9% on a year-over-year basis. Equities research analysts anticipate that Labcorp Holdings Inc. will post 18.51 earnings per share for the current fiscal year.

Labcorp Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, December 11th. Stockholders of record on Tuesday, November 24th will be paid a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a dividend yield of 0.8%. The ex-dividend date of this dividend is Tuesday, November 24th. Labcorp’s dividend payout ratio is currently 23.63%.

Analysts Set New Price Targets

LH has been the subject of several recent research reports. Morgan Stanley reissued an “overweight” rating and set a $388.00 price objective on shares of Labcorp in a research report on Thursday, October 29th. Barclays upped their target price on shares of Labcorp from $330.00 to $380.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 28th. JPMorgan Chase & Co. upped their target price on shares of Labcorp from $330.00 to $360.00 and gave the stock an “overweight” rating in a research report on Monday, August 3rd. Robert W. Baird increased their price target on shares of Labcorp from $361.00 to $396.00 and gave the stock an “outperform” rating in a research note on Thursday, October 29th. Finally, Weiss Ratings raised shares of Labcorp from a “buy (b+)” rating to a “buy (a-)” rating in a research report on Wednesday, October 21st. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, Labcorp has an average rating of “Moderate Buy” and an average price target of $369.08.

Read Our Latest Stock Analysis on LH

Insider Transactions at Labcorp

In other news, Director Richelle P. Parham sold 1,078 shares of Labcorp stock in a transaction dated Friday, October 30th. The stock was sold at an average price of $361.22, for a total value of $389,395.16. Following the completion of the transaction, the director owned 2,288 shares of the company’s stock, valued at $826,471.36. The trade was a 32.03% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Brian J. Caveney sold 2,000 shares of the company’s stock in a transaction dated Tuesday, November 10th. The stock was sold at an average price of $372.04, for a total transaction of $744,080.00. Following the completion of the transaction, the executive vice president owned 34,562 shares in the company, valued at approximately $12,858,446.48. The trade was a 5.47% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 3,384 shares of company stock valued at $1,241,707. Insiders own 0.84% of the company’s stock.

About Labcorp

(Free Report)

Labcorp (NYSE: LH), formally Laboratory Corporation of America Holdings, is a global life sciences company that provides diagnostic testing and services to patients, physicians, hospitals, employers and other health care organizations. Its offerings include routine and specialty laboratory tests, anatomic pathology and genetic testing. The company also supports pharmaceutical and biotechnology companies with laboratory services for drug development and clinical trials, including testing and analysis used in research and clinical studies.

Featured Stories

Want to see what other hedge funds are holding LH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Labcorp Holdings Inc. (NYSE:LH – Free Report).

Institutional Ownership by Quarter for Labcorp (NYSE:LH)

Receive News & Ratings for Labcorp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Labcorp and related companies with MarketBeat.com's FREE daily email newsletter.